Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz International GmbH

Division of Novartis AG

Latest From Sandoz International GmbH

Sandoz Sets Up New UK Headquarters

Sandoz has opened a new UK headquarters in Camberley that it says will help to ‘strengthen its role as a leading provider of medicines to the NHS.’

Strategy Commercial

MSD’s Ontruzant Gets Australian Reimbursement

Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.

Australia Biosimilars

Australia Lists Celltrion’s Truxima For Cancer

Celltrion Healthcare’s Truxima has become the second rituximab biosimilar to be listed on Australia’s Pharmaceutical Benefits Schedule. But unlike Sandoz’ Riximyo version, Truxima is only eligible for oncology indications under a chemotherapy funding scheme.

Australia Biosimilars

Biocon Biologics Gets True North Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Deals Strategy
See All

Company Information